(OctasaTM, FivasaTM, AsacolonTM, YaldigoTM , AsamovonTM, and KuidroTM)
Indication: For acute treatment or maintenance of remission in ulcerative colitis
Formulations: Tablet, suppository and enema
Last update: October 2024.
This medicine is only available upon prescription. The diseases or conditions for the treatment of which this product has been approved by the regulatory authority may not be the same in all countries. This product may not be available in the country where you practice medicine or reside because its supply has not been approved by the local regulatory authority. Healthcare professionals should consult the relevant officially approved prescriber’s information before prescribing or making this product available to patients. Patients and their caregivers should use this product in accordance with the advice of a healthcare professional and the patient information officially approved in their country of residence.